Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-23-023834
Date:2023-02-16
Issuer: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Original Submission Date:

Reporting Person:

MARTIN TAMI TILLOTSON
C/O SUPERNUS PHARMACEUTICALS, INC.
9715 KEY WEST AVENUE ROCKVILLE, MD 20850

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2023-02-16 M 1,500 a $0.00 88,720 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
PERFORMANCE SHARE UNIT 0.0 2023-02-16 deemed execution date M 1,500 (d) 2031-04-30 common stock 1,500 $0.00 0 direct
Footnotes
IDfootnote
f1 shares of common stock received upon the settlement of certain performance share units granted to the reporting person on april 30, 2021.
f2 on april 30, 2021, the reporting person was awarded performance share units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.
WhaleWisdom Logo

Elevate your investments